Physician profile
Jordan Staton
NPI 1669810149
$1,430.48
in general payments reported to CMS, 2019-2025
23 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $340 · 2024: $607 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $234.67 | 2023-2025 | Myfembree, Gemtesa |
| Sage Therapeutics, LLC | $226.31 | 2023-2025 | Zurzuvae |
| Astellas Pharma US INC | $124.20 | 2024-2025 | Veozah |
| Exeltis, USA INC. | $109.25 | 2022-2025 | Slynd |
| Abbvie INC. | $94.07 | 2022-2024 | Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $74.70 | 2023-2025 | |
| Novo Nordisk INC | $70.04 | 2024-2025 | Wegovy |
| Mayne Pharma Commercial LLC | $62.77 | 2023-2025 | |
| Aspira Women'S Health INC | $61.82 | 2023 | Ova1 |
| Myovant Sciences INC. | $57.52 | 2022 | |
| Daiichi Sankyo INC. | $48.15 | 2022-2024 | Injectafer |
| Organon LLC | $41.41 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $31.48 | 2022-2023 | Gardasil 9 |
| Millicent US INC | $30.11 | 2024 | Intrarosa |
| Hologic Sales and Service, LLC | $29.78 | 2024-2025 | Myosure Tissue Removal Device, Novasure |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $19.40 | 2022 | |
| Medtronic, INC. | $18.92 | 2025 | Venaseal |
| Integra Lifesciences Corporation | $18.75 | 2025 | Tenoglide |
| Shield Therapeutics INC | $17.68 | 2024 | |
| Pfizer INC. | $17.63 | 2024 | |
| Smith+Nephew, INC. | $14.55 | 2023 | Pico |
| Baxter Healthcare | $13.78 | 2023 | Seprafilm |
| Lilly USA, LLC | $13.49 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Staton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.